IFPMA

We represent the innovative pharmaceutical industry globally, with a focus on three priorities: innovation, equitable access, and ethics. #AlwaysInnovating

[IFPMA @IFPMA]

Investing in innovative medicines and vaccines doesn’t just save lives - it transforms our future. It strengthens health, drives economic growth, and improves health security.

#AlwaysInnovating

[IFPMA @IFPMA]

#NCDs are both a health and an economic challenge. IFPMA Executive Director, Global Health, Access, and Financing, Derrick Sim, makes the case for treating NCDs as an investment in healthier lives, stronger labor markets, and more resilient economies 👇

https://t.co/foqH8TclJm

[Global Governance Media @GloGovMedia]

Pharmaceutical innovation is not only an investment in health, but also in economic growth and resilience. @IFPMA Director General Dr. David Reddy examines why sustained investment in research and innovation is critical to healthier populations and stronger economies.
#HealthAPoliticalChoice #WHS2026 #HealthInnovation #GlobalHealth @WorldHealthSmt @IFPMA
https://t.co/k2xUvrxfDo

[IFPMA @IFPMA]

On #WorldHeartDay, we’re reminded how prevention and innovation help people live healthier lives. CVRM conditions drive nearly half of NCD deaths, yet new diagnostics and treatments are transforming how we manage their interconnected progression.

🔗 https://t.co/u7SoI5l8j2

[IFPMA @IFPMA]

Global health #security remains fragile. The #Ebola outbreak underscores the need for sustained investment in pharmaceutical innovation, stronger health systems, & policy and financing frameworks that make scientific progress possible.

Learn more 👇
https://t.co/tY5iYmSUXB

[IFPMA @IFPMA]

Fostering innovation, strengthening health systems, and effective partnerships must be global priorities for today's global health architecture reform.

Read the op-ed by @DavidReddyIFPMA on @HealthPolicyWatch 👇

https://t.co/dLhe0gNpEF

[IFPMA @IFPMA]

Adult #immunization is vital for healthy aging. By 2060, adults 55–64 will be 30% of the workforce. Each $1 invested returns up to 19×, while preventable diseases cost G20 economies $1T yearly.

🔗 Learn more:
https://t.co/pUPi3a4J3d

[IFPMA @IFPMA]

🌍 As clinical research becomes increasingly global, greater convergence in clinical trial review processes can make all the difference by reducing delays and helping patients access innovative therapies faster, wherever they are.

📖 Download now:
https://t.co/hI5FHC0KBr

[IFPMA @IFPMA]

1 in 3 people globally live with an NCD. 82% of premature NCD deaths happen in low- and middle-income countries.

140+ initiatives on #GlobalHealthProgress show how partnerships are closing that gap 👇

https://t.co/USPR3nQNiX

#AlwaysInnovating #LeadOnNCDs #ActOnNCDs

[IFPMA @IFPMA]

As populations age and #NCDs rise, fewer workers support more with chronic illness.

Adults with #CVD are 10x more likely to suffer a heart attack after flu. NCDs cost the EU ~€437.7B/year in lost productivity.

🔗https://t.co/sjwclwUlgs

#AlwaysInnovating #LeadOnNCDs #ActOnNCDs

[IFPMA @IFPMA]

#Prevention is one of our most powerful tools against #NCDs.

Adult immunization is cost-effective, slows disease progression, cuts healthcare needs, and helps people stay independent in education or work.

🔗https://t.co/FqrM7lpD1c

#AlwaysInnovating #LeadOnNCDs #ActOnNCDs

[IFPMA @IFPMA]

Nearly half of NCD deaths link to preventable, interlinked cardiovascular, renal & metabolic (#CVRM) conditions.

Breakthroughs are transforming care for the 30-40% of people living with multimorbidities.

🔗 https://t.co/8Q9FTNWePB

#AlwaysInnovating #LeadOnNCDs #ActOnNCDs

[IFPMA @IFPMA]

Medicines have transformed how the world fights #NCDs. The industry has launched 1,400+ new medicines in the past decade, with 9,600+ more in development.

🔗 Learn more:
https://t.co/6lSrPSxb5x

#AlwaysInnovating #LeadOnNCDs #ActOnNCDs

[IFPMA @IFPMA]

100 days since the #Ebola outbreak was declared in the DRC, IFPMA and @IAmBiotech underline the industry's track record on health emergencies and call for a #PABS system that strengthens industry engagement in pandemic response.

🔗Read the news release:
https://t.co/WF5CLD9tc0

[IFPMA @IFPMA]

Preventable diseases cost #G20 economies over USD 1 trillion annually in productivity among people aged 50–64.

Our new infographic with #GCOA explores vaccination as strategic economic infrastructure for productivity, healthy ageing, and preparedness.

https://t.co/MSWXvIWFac

[IFPMA @IFPMA]

#AI and Machine Learning are rapidly transforming pharmaceutical manufacturing.

IFPMA’s new position paper explores how the industry can apply AI in manufacturing and control and offers key considerations for national regulatory authorities.

🔗 https://t.co/ki9ppwalYL

[IFPMA @IFPMA]

🌎 Global Health Progress is an interactive resource hub spotlighting collaborations between the innovative pharmaceutical industry and global partners to advance the #SDGs.

See the numbers behind the impact:
🔗 https://t.co/w9givfvApi

[IFPMA @IFPMA]

How can data‑driven insights help improve the safety, efficacy, and effectiveness of care worldwide?

IFPMA’s new publication explores how every patient interaction generates information that can advance healthcare when used responsibly.

https://t.co/uYQgfwXwCa

[IFPMA @IFPMA]

Routine immunization isn't just a health service, it is core to health security, shaping how fast countries respond when a crisis emerges.

Read more by IFPMA's Laetitia Agostini Bigger in @MediaplanetUK's Global Health Resilience and @guardian campaign:

https://t.co/K82uIIEHxi

[IFPMA @IFPMA]

IFPMA’s new publication explores the R&D ecosystem for medicines and vaccines, highlighting the conditions needed to sustain innovation and ensure scientific progress translates into benefits for people, economies, and societies.

https://t.co/xAktZgMvGy

[IFPMA @IFPMA]

Adult immunization is a high-impact, cost-effective investment in economic growth & societal resilience, yet is underinvested, leaving economies exposed to avoidable costs.

Read more in our position paper:

🔗 https://t.co/sjwclwUlgs